Stojanovic Bojan, Gajovic Nevena, Jurisevic Milena, Stojanovic Milica Dimitrijevic, Jovanovic Marina, Jovanovic Ivan, Stojanovic Bojana S, Milosevic Bojan
Department of Surgery, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Int J Mol Sci. 2023 Sep 13;24(18):14026. doi: 10.3390/ijms241814026.
Interleukin-33 (IL-33) has emerged as a critical cytokine in the regulation of the immune system, showing a pivotal role in the pathogenesis of various diseases including cancer. This review emphasizes the role of the IL-33/ST2 axis in breast cancer biology, its contribution to cancer progression and metastasis, its influence on the tumor microenvironment and cancer metabolism, and its potential as a therapeutic target. The IL-33/ST2 axis has been shown to have extensive pro-tumorigenic features in breast cancer, starting from tumor tissue proliferation and differentiation to modulating both cancer cells and anti-tumor immune response. It has also been linked to the resistance of cancer cells to conventional therapeutics. However, the role of IL-33 in cancer therapy remains controversial due to the conflicting effects of IL-33 in tumorigenesis and anti-tumor response. The possibility of targeting the IL-33/ST2 axis in tumor immunotherapy, or as an adjuvant in immune checkpoint blockade therapy, is discussed.
白细胞介素-33（IL-33）已成为免疫系统调节中的一种关键细胞因子，在包括癌症在内的各种疾病的发病机制中发挥着关键作用。本综述强调了IL-33/ST2轴在乳腺癌生物学中的作用、其对癌症进展和转移的贡献、其对肿瘤微环境和癌症代谢的影响以及其作为治疗靶点的潜力。IL-33/ST2轴已被证明在乳腺癌中具有广泛的促肿瘤特征，从肿瘤组织增殖和分化到调节癌细胞和抗肿瘤免疫反应。它还与癌细胞对传统疗法的耐药性有关。然而，由于IL-33在肿瘤发生和抗肿瘤反应中的作用相互矛盾，其在癌症治疗中的作用仍存在争议。本文讨论了在肿瘤免疫治疗中靶向IL-33/ST2轴或作为免疫检查点阻断治疗佐剂的可能性。
Zotero 插件
